πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10100020

Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfoldi

United Kingdom Research and Innovation Β· Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10100049

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC Β· Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10092580

Controlled-release otic structure modulating and innate immune system modulating compositi

The Regents of the University of California Β· Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10092596

Tungstate treatment of the dysbiosis associated with gastrointestinal inflammation

The Regents of the University of California Β· Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10093664

Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of

The Board of Regents of the University of Texas System Β· Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10093745

Anti-CSPG4 fusions with interferon for the treatment of malignancy

The Regents of the University of California Β· Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10087444

MicroRNA composition for the treatment of neuroblastoma

The Board of Regents of the University of Texas System Β· Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10085951

Curcuminoid formulations and related methods of treatment

DESIGNS FOR HEALTH, INC. Β· Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10080749

Multi-drug therapies for tuberculosis treatment

The Regents of the University of California Β· Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10080730

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

United Therapeutics Corporation Β· Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10077296

Methods and compositions for the treatment and prevention of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10076520

Use of tyrosine kinase inhibitor in cancer treatment

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10071123

Treatment of pulmonary arterial hypertension with mesenchymal stem cells

United Therapeutics Corporation Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10071945

Nuclear receptor modulators and their use for the treatment and prevention of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10071095

1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurologica

Addex Pharma, S.A. Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072066

Methods and compositions for treatment of a beta thalessemia

Sangamo Therapeutics, Inc. Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10071083

Use of gaboxadol in the treatment of tinnitus

OVID THERAPEUTICS INC. Β· Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10058587

Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

Soricimed Biopharma Inc. Β· Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10058556

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. Β· Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10058559

Treatment or prevention of an intestinal disease or disorder

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10052363

Mesenchymal stem cells for the treatment of CNS diseases

BRAINSTORM CELL THERAPEUTICS LTD. Β· Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10052371

Compositions and methods for treatment of cancer using bacteria

Decoy Biosystems, Inc. Β· Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10052393

Multifunctional nanomaterials for the treatment of cancer

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10046036

Chemically modified cystathionine Ξ²-synthase enzyme for treatment of homocystinuria

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted